Toronto company selling IPRO, an AI model that generates survival predictions from routine CT scans to accelerate drug efficacy evaluation in oncology clinical trials.
Canadian innovation builds a brighter tomorrow.
Toronto company selling IPRO, an AI model that generates survival predictions from routine CT scans to accelerate drug efficacy evaluation in oncology clinical trials.
ALTIS LABS, INC. is an active federal Business Corporation with registered office in Toronto, Ontario, incorporated 2019-03-28; office listed at the MaRS Centre, Toronto. ised-isde.canada.ca
Raised a US$25 million Series A on 2026-09-17, co-led by OrbiMed and Qiming Venture Partners USA, with several other investors participating. altislabs.com
Entered a multi-year collaboration with Johnson & Johnson Innovative Medicine to accelerate clinical development using its computational imaging platform. altislabs.com
Partnered with University Health Network on a multi-year collaboration to leverage AI in cancer imaging, and with Hamilton Health Sciences on AI for breast cancer applications. altislabs.com
Products Altis Labs publishes on its own site. Each card links to the page it was taken from.
AI imaging endpoints
AI model that generates survival predictions from routinely acquired CT scans in oncology clinical trials, presented as outperforming RECIST 1.1 in predicting overall survival across lung, colorectal and breast cancer trial data.
Learn more SourceAnnounced rounds only, newest first. Undisclosed amounts are shown as undisclosed.
Sep 17, 2026
Investors: OrbiMed, Qiming Venture Partners USA, Innovation Endeavors, Benchstrength, Fusion Fund, Lumira Ventures (Cancer Breakthrough Fund)
Jun 21, 2023
Publicly announced partnerships.
Multi-year collaboration to accelerate clinical development with AI using Altis' computational imaging platform.
Multi-year collaboration to leverage AI in cancer imaging.
Collaboration applying Altis' AI imaging platform to breast cancer.
Altis Labs closed a US$25 million Series A co-led by OrbiMed and Qiming Venture Partners USA to expand its AI models across additional cancer types and scale commercial deployment with global biopharmaceutical partners.
Altis Labs entered a multi-year collaboration agreement with Johnson & Johnson Innovative Medicine focused on accelerating clinical development using Altis' computational imaging platform.
Sourced from the company's own pages or announcements.
Felix Baldauf-Lenschen
Founder & Chief Executive Officer
Terms the company uses about its own work.
Other companies in AI.
Discover companies, track funding, explore career opportunities and stay informed about Canada’s growing tech ecosystem.
